HIV treatment as prevention: Optimising the impact of expanded HIV treatment programmes

PLoS Medicine

Volumn 9, Issue 7, 2012, Pages

  Delva, Wim ^a,b   Eaton, Jeffrey W ^c   Meng, Fei ^b,d   Fraser, Christophe ^c   White, Richard G ^e   Vickerman, Peter ^e   Boily, Marie Claude ^c   Hallett, Timothy B ^c  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b GHENT UNIVERSITY   (Belgium)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d HASSELT UNIVERSITY   (Belgium)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE HOMOSEXUAL; MORBIDITY; MORTALITY; PREGNANT WOMAN; PRENATAL CARE; PROSTITUTION; REVIEW; TUBERCULOSIS; VIRUS LOAD; VIRUS TRANSMISSION; DISEASE TRANSMISSION; ECONOMICS; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HEALTH PLANNING; HIV INFECTIONS; HUMANS;

EID: 84864485996     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001258     Document Type: Review

References (132)

1. World Health Organization, Joint United Nations Programme on HIV/AIDS, United Nations Children's Fund (2011) Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011 Geneva World Health Organization Available: http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf. Accessed 13 December 2011.
2. Sadr WE, Cohen M, DeCock K, Bekker LG, Karim S, et al. (2011) PEPFAR Scientific Advisory Board recommendations for the Office of the US Global AIDS Coordinator: implications of HPTN 052 for PEPFAR's treatment programs Washington (District of Columbia) Office of the US Global AIDS Coordinator.
3. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision Geneva World Health Organization.
4. Cohen J, (2011) Breakthrough of the year. HIV treatment as prevention. Science 334: 1628.
5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
6. Hargrove JW, Humphrey JH, (2010) Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 24: F11-F14.
7. (2010) Funding, other trends imperil global response to HIV/AIDS. AIDS Policy Law 25: 4.
8. Geng EH, Bwana MB, Kabakyenga J, Muyindike W, Emenyonu NI, et al. (2010) Diminishing availability of publicly funded slots for antiretroviral initiation among HIV-infected ART-eligible patients in Uganda. PLoS ONE 5: e14098 doi:10.1371/journal.pone.0014098.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents (2011) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Washington (District of Columbia) US Department of Health and Human Services Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 4 January 2012.
10. European AIDS Clinical Society (2011) Guidelines: version 6-October 2011. Available: http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6.0-English.pdf. Accessed 12 June 2012.
11. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375: 2092-2098.
12. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373: 1352-1363.
13. Van Cutsem G, Ford N, Hildebrand K, Goemaere E, Mathee S, et al. (2011) Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS ONE 6: e14684 doi:10.1371/journal.pone.0014684.
14. ClinicalTrials.gov (2012) Strategic Timing of Antiretroviral Treatment (START). Available: http://clinicaltrials.gov/ct2/show/NCT00867048. Accessed 4 January 2012.
15. Stover J, Bollinger L, Avila C, (2011) Estimating the impact and cost of the WHO 2010 recommendations for antiretroviral therapy. AIDS Res Treat 2011: 738271.
16. Joint United Nations Programme on HIV/AIDS (2011) UNAIDS world AIDS day report 2011: how to get to zero. faster. smarter. better Geneva Joint United Nations Programme on HIV/AIDS.
17. Rosen S, Fox MP, (2011) Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 8: e1001056 doi:10.1371/journal.pmed.1001056.
18. Kranzer K, Zeinecker J, Ginsberg P, Orrell C, Kalawe NN, et al. (2010) Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS ONE 5: e13801 doi:10.1371/journal.pone.0013801.
19. Novitsky V, Ndung'u T, Wang R, Bussmann H, Chonco F, et al. (2011) Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS 25: 1515-1522.
20. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, et al. (1990) Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr 3: 144-151.
21. Raboud JM, Haley L, Montaner JS, Murphy C, Januszewska M, et al. (1995) Quantification of the variation due to laboratory and physiologic sources in CD4 lymphocyte counts of clinically stable HIV-infected individuals. J Acquir Immune Defic Synd 10 (Suppl 2): S67-S73.
22. Katz IT, Essien T, Marinda ET, Gray GE, Bangsberg DR, et al. (2011) Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS 25: 2177-2181.
23. Geskus RB, Prins M, Hubert JB, Miedema F, Berkhout B, et al. (2007) The HIV RNA setpoint theory revisited. Retrovirology 4: 65.
24. Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP, (2007) Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci U S A 104: 17441-17446.
25. Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, et al. (2011) Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 3: 77ra29.
26. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342: 921-929.
27. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, et al. (2001) Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 17: 901-910.
28. Lingappa JR, Hughes JP, Wang RS, Baeten JM, Celum C, et al. (2010) Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS ONE 5: e12598 doi:10.1371/journal.pone.0012598.
29. Wang S, Xu F, Demirci U, (2010) Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv 28: 770-781.
30. de Wolf F, Spijkerman I, Schellekens PT, Langendam M, Kuiken C, et al. (1997) AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 11: 1799-1806.
31. Boily MC, Mâsse B, Alsallaq R, Padian NS, Eaton JW, et al. (2012) HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med 9: e1001250 doi:10.1371/journal.pmed.1001250.
32. Novitsky V, Wang R, Bussmann H, Lockman S, Baum M, et al. (2010) HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. PLoS ONE 5: e10148 doi:10.1371/journal.pone.0010148.
33. World Health Organization (2010) Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach-2010 version Geneva World Health Organization.
34. Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, et al. (2011) Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 378: 282-284.
35. Lesotho Ministry of Health and Social Welfare, ICF Macro (2010) Lesotho Demographic and Health Survey 2009. Calverton (Maryland): Ministry of Health and Social Welfare and ICF Macro.
36. Malawi National Statistical Office, ICF Macro (2011) Malawi Demographic and Health Survey 2010. Calverton (Maryland): Malawi National Statistical Office and ICF Macro.
37. Kenya National Bureau of Statistics, ICF Macro, (2010) Kenya Demographic and Health Survey 2008-09. Calverton (Maryland): Kenya National Bureau of Statistics and ICF Macro.
38. Mugo NR, Heffron R, Donnell D, Wald A, Were EO, et al. (2011) Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS 25: 1887-1895.
39. Patel D, Cortina-Borja M, Thorne C, Newell ML, (2007) Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 44: 1647-1656.
40. United Nations Department of Economic and Social Affairs Population Division (2011) World population prospects, the 2010 revision New York United Nations Available: http://esa.un.org/unpd/wpp/index.htm. Accessed 19 December 2011.
41. Ekouevi DK, Inwoley A, Tonwe-Gold B, Danel C, Becquet R, et al. (2007) Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings. AIDS Res Hum Retroviruses 23: 1469-1474.
42. Côte d'Ivoire Institut National de la Statistique, ORC Macro (2006) Enquête sur les indicateurs du sida, Côte d'Ivoire 2005. Calverton (Maryland): Côte d'Ivoire Institut National de la Statistique and ORC Macro.
43. Oladokun RE, Awolude O, Brown BJ, Adesina O, Oladokun A, et al. (2010) Service uptake and performance of the prevention of mother-to-child transmission (PMTCT) programme in Ibadan, Nigeria. Afr J Med Med Sci 39: 81-87.
44. Holmes CN, Preko PO, Bolds R, Baidoo J, Jolly PE, (2008) Acceptance of voluntary counselling, testing and treatment for HIV among pregnant women in Kumasi, Ghana. Ghana Med J 42: 8-15.
45. Geddes R, Giddy J, Butler LM, Van Wyk E, Crankshaw T, et al. (2011) Dual and triple therapy to prevent mother-to-child transmission of HIV in a resource-limited setting-lessons from a South African programme. S Afr Med J 101: 651-654.
46. Torpey K, Kabaso M, Kasonde P, Dirks R, Bweupe M, et al. (2010) Increasing the uptake of prevention of mother-to-child transmission of HIV services in a resource-limited setting. BMC Health Serv Res 10: 29.
47. Bancheno WM, Mwanyumba F, Mareverwa J, (2010) Outcomes and challenges of scaling up comprehensive PMTCT services in rural Swaziland, Southern Africa. AIDS Care 22: 1130-1135.
48. Hensen B, Baggaley R, Wong VJ, Grabbe KL, Shaffer N, et al. (2011) Universal voluntary HIV testing in antenatal care settings: a review of the contribution of provider-initiated testing & counselling. Trop Med Int Health. E-pub ahead of print doi:10.1111/j.1365-3156.2011.02893.x.
49. Ferguson L, Grant AD, Watson-Jones D, Kahawita T, Ong'ech JO, et al. (2012) Linking women who test HIV-positive in pregnancy-related services to long-term HIV care and treatment services: a systematic review. Trop Med Int Health. E-pub ahead of print doi:10.1111/j.1365-3156.2012.02958.x.
50. Toro PL, Katyal M, Carter RJ, Myer L, El-Sadr WM, et al. (2010) Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention. AIDS 24: 515-524.
51. Boyles TH, Wilkinson LS, Leisegang R, Maartens G, (2011) Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme. PLoS ONE 6: e19201 doi:10.1371/journal.pone.0019201.
52. Bwirire LD, Fitzgerald M, Zachariah R, Chikafa V, Massaquoi M, et al. (2008) Reasons for loss to follow-up among mothers registered in a prevention-of-mother-to-child transmission program in rural Malawi. Trans R Soc Trop Med Hyg 102: 1195-1120.
53. Johri M, Ako-Arrey D, (2011) The cost-effectiveness of preventing mother-to-child transmission of HIV in low- and middle-income countries: systematic review. Cost Eff Resour Alloc 9: 3.
54. Shah M, Johns B, Abimiku A, Walker DG, (2011) Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in a resource-limited setting. AIDS 25: 1903-1102.
55. United Nations Development Programme (2010) What will it take to achieve the Millennium Development Goals? An international assessment New York United Nations Development Programme.
56. van den Akker T, Bemelmans M, Ford N, Jemu M, Diggle E, et al. (2012) HIV care need not hamper maternity care: a descriptive analysis of integration of services in rural Malawi. BJOG 199: 431-438.
57. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. New Engl J Med 362: 697-706.
58. World Health Organization (2011) Global tuberculosis control: WHO report 2011 Geneva World Health Organization.
59. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, et al. (1996) Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 157: 1271-1278.
60. Toossi Z, Mayanja-Kizza H, Hirsch CS, Edmonds KL, Spahlinger T, et al. (2001) Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol 123: 233-238.
61. Wolday D, Hailu B, Girma M, Hailu E, Sanders E, et al. (2003) Low CD4+ T-cell count and high HIV viral load precede the development of tuberculosis disease in a cohort of HIV-positive ethiopians. Int J Tuberc Lung Dis 7: 110-116.
62. Day JH, Grant AD, Fielding KL, Morris L, Moloi V, et al. (2004) Does tuberculosis increase HIV load? J Infect Dis 190: 1677-1684.
63. Mahan CS, Walusimbi M, Johnson DF, Lancioni C, Charlebois E, et al. (2010) Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count. PLoS ONE 5: e9138 doi:10.1371/journal.pone.0009138.
64. Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, et al. (2010) Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A 107: 19485-19489.
65. Badri M, Wilson D, Wood R, (2002) Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359: 2059-2064.
66. World Health Organization (2009) Global tuberculosis control 2009: epidemiology, strategy, financing Geneva World Health Organization.
67. Gandhi NR, Moll AP, Lalloo U, Pawinski R, Zeller K, et al. (2009) Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr 50: 37-43.
68. Sterling TR, Pham PA, Chaisson RE, (2010) HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis 50 (Suppl 3): S223-S230.
69. World Health Organization (2012) Guidance on couples HIV Testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples Geneva World Health Organization.
70. Ware NC, (2011) What's love got to do with it?-a relationship framework for research on adherence to antiretroviral therapy (ART) as pre-exposure prophylaxis [abstract]. 6th International Conference on HIV Treatment and Prevention Adherence; 22-24 May 2011; Miami Beach, Florida.
71. Cohen MS, Muessig KE, Smith MK, Powers K, Kashuba AD, (2012) Antiviral agents and HIV prevention: controversies, conflicts and consensus. AIDS. E-pub ahead of print doi:10.1097/QAD.0b013e3283543e83.
72. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, et al. (2011) Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 8: e1001123 doi:10.1371/journal.pmed.1001123.
73. Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, et al. (2011) HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy in Rakai, Uganda. AIDS 25: 473-477.
74. El-Sadr WM, Coburn BJ, Blower S, (2011) Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS 25: 2295-2299.
75. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, et al. (2012) HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 9: e1001245 doi:10.1371/journal.pmed.1001245.
76. Lingappa JR, Lambdin B, Bukusi EA, Ngure K, Kavuma L, et al. (2008) Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS ONE 3: e1411 doi:10.1371/journal.pone.0001411.
77. Chemaitelly H, Cremin I, Shelton J, Hallett T, Abu-Raddad LJ, (2012) Distinct HIV discordancy patterns by epidemic size in stable sexual partnerships in sub-Saharan Africa. Sex Transm Infect 88: 51-57.
78. Tumwesigye E, Baeten J, Tumwebaze H, Kurth A, Revall J, et al. (2011) Potential of household-based HIV counseling and testing as a platform for targeted referral to HIV prevention and care in Uganda [abstract]. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 17-20 July 2011; Rome, Italy.
79. Joint United Nations Programme on HIV/AIDS (2011) UNAIDS terminology guidelines Geneva Joint United Nations Programme on HIV/AIDS.
80. Pisani E, Garnett GP, Brown T, Stover J, Grassly NC, et al. (2003) Back to basics in HIV prevention: focus on exposure. BMJ 326: 1384-1387.
81. Vickerman P, Foss AM, Pickles M, Deering K, Verma S, et al. (2010) To what extent is the HIV epidemic in southern India driven by commercial sex? A modelling analysis. AIDS 24: 2563-2572.
82. Boily MC, Lowndes C, Alary M, (2002) The impact of HIV epidemic phases on the effectiveness of core group interventions: insights from mathematical models. Sex Transm Infect 78 (Suppl 1): i78-i90.
83. Cote AM, Sobela F, Dzokoto A, Nzambi K, Asamoah-Adu C, et al. (2004) Transactional sex is the driving force in the dynamics of HIV in Accra, Ghana. AIDS 18: 917-925.
84. Alary M, Lowndes CM, (2004) The central role of clients of female sex workers in the dynamics of heterosexual HIV transmission in sub-Saharan Africa. AIDS 18: 945-947.
85. Gouws E, White PJ, Stover J, Brown T, (2006) Short term estimates of adult HIV incidence by mode of transmission: Kenya and Thailand as examples. Sex Transm Infect 82 (Suppl 3): iii51-iii55.
86. Quan VM, Chung A, Long HT, Dondero TJ, (2000) HIV in Vietnam: the evolving epidemic and the prevention response, 1996 through 1999. J Acquir Immune Defic Syndr 25: 360-369.
87. Park LS, Siraprapasiri T, Peerapatanapokin W, Manne J, Niccolai L, et al. (2010) HIV transmission rates in Thailand: evidence of HIV prevention and transmission decline. J Acquir Immune Defic Syndr 54: 430-436.
88. Lowndes CM, Alary M, Belleau M, Bosu W, Kintin D, et al. (2008) West Africa HIV/AIDS epidemiology and response synthesis. Characterisation of the HIV epidemic and response in West Africa: implications for prevention Washington (District of Columbia) World Bank.
89. Ng M, Gakidou E, Levin-Rector A, Khera A, Murray CJ, et al. (2011) Assessment of population-level effect of Avahan, an HIV-prevention initiative in India. Lancet 378: 1643-1652.
90. Shahmanesh M, Patel V, Mabey D, Cowan F, (2008) Effectiveness of interventions for the prevention of HIV and other sexually transmitted infections in female sex workers in resource poor setting: a systematic review. Trop Med Int Health 13: 659-679.
91. McClelland L, Wanje G, Kashonga F, Kibe L, McClelland RS, et al. (2011) Understanding the context of HIV risk behavior among HIV-positive and HIV-negative female sex workers and male bar clients following antiretroviral therapy rollout in Mombasa, Kenya. AIDS Educ Prev 23: 299-312.
92. Braunstein SL, Umulisa MM, Veldhuijzen NJ, Kestelyn E, Ingabire CM, et al. (2011) HIV diagnosis, linkage to HIV care, and HIV risk behaviors among newly diagnosed HIV-positive female sex workers in Kigali, Rwanda. J Acquir Immune Defic Syndr 57: e70-e76.
93. Huet C, Ouedraogo A, Konate I, Traore I, Rouet F, et al. (2011) Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa. BMC Public Health 11: 700.
94. McClelland RS, Graham SM, Richardson BA, Peshu N, Masese LN, et al. (2010) Treatment with antiretroviral therapy is not associated with increased sexual risk behavior in Kenyan female sex workers. AIDS 24: 891-897.
95. McKinnon LR, Kimani M, Wachihi C, Nagelkerke NJ, Muriuki FK, et al. (2010) Effect of baseline HIV disease parameters on CD4+ T cell recovery after antiretroviral therapy initiation in Kenyan women. PLoS ONE 5: e11434 doi:10.1371/journal.pone.0011434.
96. Deering KN, Shannon K, Sinclair H, Parsad D, Gilbert E, et al. (2009) Piloting a peer-driven intervention model to increase access and adherence to antiretroviral therapy and HIV care among street-entrenched HIV-positive women in Vancouver. AIDS Patient Care STDS 23: 603-609.
97. Shannon K, Bright V, Duddy J, Tyndall MW, (2005) Access and utilization of HIV treatment and services among women sex workers in Vancouver's Downtown Eastside. J Urban Health 82: 488-497.
98. Chan CH, McCabe CJ, Fisman DN, (2011) Core groups, antimicrobial resistance and rebound in gonorrhoea in North America. Sex Transm Infect 88: 200-204.
99. Kennedy C, O'Reilly K, Medley A, Sweat M, (2007) The impact of HIV treatment on risk behaviour in developing countries: a systematic review. AIDS Care 19: 707-720.
100. Montague BT, Vuylsteke B, Buve A, (2011) Sustainability of programs to reach high risk and marginalized populations living with HIV in resource limited settings: implications for HIV treatment and prevention. BMC Public Health 11: 701.
101. Verma R, Shekhar A, Khobragade S, Adhikary R, George B, et al. (2010) Scale-up and coverage of Avahan: a large-scale HIV-prevention programme among female sex workers and men who have sex with men in four Indian states. Sex Transm Infect 86 (Suppl 1): i76-i82.
102. Alary M, Mukenge Tshibaka L, Bernier F, Geraldo N, Lowndes CM, et al. (2002) Decline in the prevalence of HIV and sexually transmitted diseases among female sex workers in Cotonou, Benin, 1993-1999. AIDS 16: 463-470.
103. Ghys PD, Diallo MO, Ettiegne Traore V, Kale K, Tawil O, et al. (2002) Increase in condom use and decline in HIV and sexually transmitted diseases among female sex workers in Abidjan, Cote d'Ivoire, 1991-1998. AIDS 16: 251-258.
104. Chandrashekar S, Guinness L, Kumaranayake L, Reddy B, Govindraj Y, et al. (2010) The effects of scale on the costs of targeted HIV prevention interventions among female and male sex workers, men who have sex with men and transgenders in India. Sex Transm Infect 86 (Suppl 1): i89-i94.
105. Creese A, Floyd K, Alban A, Guinness L, (2002) Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 359: 1635-1643.
106. Vickerman P, Terris-Prestholt F, Delany S, Kumaranayake L, Rees H, et al. (2006) Are targeted HIV prevention activities cost-effective in high prevalence settings? Results from a sexually transmitted infection treatment project for sex workers in Johannesburg, South Africa. Sex Transm Dis 33 (Suppl 10): S122-S132.
107. Diabate S, Zannou D, Geraldo N, Chamberland A, Akakpo J, et al. (2011) Antiretroviral therapy among HIV-1 infected female sex workers in Benin: a comparative study with patients from the general population. World J AIDS 1: 94-99.
108. Rodriguez-Arenas MA, Jarrin I, del Amo J, Iribarren JA, Moreno S, et al. (2006) Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses 22: 715-723.
109. Watts C, Zimmerman C, Foss AM, Hossain M, Cox A, et al. (2010) Remodelling core group theory: the role of sustaining populations in HIV transmission. Sex Transm Infect 86 (Suppl 3): iii85-iii92.
110. Boily MC, William J, Alary M, (2011) Impact of female sex worker turnover on HIV prevalence, incidence and core group intervention impact in Cotonou (Benin) [poster]. 19th Biennial Conference of the International Society for Sexually Transmitted Diseases Research; 10-14 July 2011; Quebec City, Canada.
111. Pickles M, Boily MC, Vickerman P, Ramesh BM, Washington R, et al. (2011) Time evolution of the fraction of new HIV infections due to primary infection among high risk groups in southern India [poster]. 19th Biennial Conference of the International Society for Sexually Transmitted Diseases Research; 10-14 July 2011; Quebec City, Canada.
112. Vickerman P, Watts C, Delany S, Alary M, Rees H, et al. (2006) The importance of context: model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sex Transm Dis 33: 397-405.
113. Boily MC, Lowndes C, Alary M, (2000) Complementary hypothesis concerning the community sexually transmitted disease mass treatment puzzle in Rakai, Uganda. AIDS 14: 2583-2592.
114. Geibel S, van der Elst EM, King'ola N, Luchters S, Davies A, et al. (2007) 'Are you on the market?': a capture-recapture enumeration of men who sell sex to men in and around Mombasa, Kenya. AIDS 21: 1349-1354.
115. van Griensven F, (2007) Men who have sex with men and their HIV epidemics in Africa. AIDS 21: 1361-1362.
116. Joint United Nations Programme on HIV/AIDS (2010) New HIV infections by mode of transmission in West Africa: A multicountry analysis Geneva Joint United Nations Programme on HIV/AIDS.
117. Mathers B, Degenhardt L, Phillips B, Wiessing L, Hickman M, et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372: 1733-1745.
118. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, et al. (2010) HIV and risk environment for injecting drug users: the past, present, and future. Lancet 376: 268-284.
119. Joint United Nations Programme on HIV/AIDS (2009) KENYA HIV prevention response and modes of transmission analysis Geneva Joint United Nations Programme on HIV/AIDS.
120. Wolfe D, Carrieri MP, Shepard D, (2010) Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 376: 355-366.
121. Malta M, Magnanini MM, Strathdee SA, Bastos FI, (2010) Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 14: 731-747.
122. Ndiaye B, Ould-Kaci K, Salleron J, Bataille P, Bonnevie F, et al. (2009) Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France-January 1997 to December 2006. Antivir Ther 14: 567-575.
123. Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, et al. (2008) Loss to follow-up in an international, multicentre observational study. HIV Med 9: 261-269.
124. Rosen S, Sanne I, Collier A, Simon JL, (2005) Rationing antiretroviral therapy for HIV/AIDS in Africa: choices and consequences. PLoS Med 2: e303 doi:10.1371/journal.pmed.0020303.
125. Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, et al. (2011) Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 9: 446-469.
126. International Maternal Pediatric Adolescent AIDS Clinical Trials Group (2010) PROMISE featured study-1077HS. Available: https://impaactgroup.org/promise-featured-study-1077hs. Accessed June 8, 2012.
127. Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, et al. (2010) Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 24: 2263-2270.
128. Nachega JB, Morroni C, Zuniga JM, Schechter M, Rockstroh J, et al. (2012) HIV treatment adherence, patient health literacy, and health care provider-patient communication: results from the 2010 AIDS Treatment for Life International Survey. J Int Assoc Physicians AIDS Care (Chic) 11: 128-133.
129. Thompson MA, Mugavero MJ, Amico KR, Chang LW, Gross R, et al. (2012) Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. Ann Intern Med 156: 817-833.
130. World Health Organization (2003) Making choices in health: generalized cost effectiveness analysis: a guide Geneva World Health Organization.
131. World Health Organization (2011) WHO consultation on the strategic use of antiretrovirals for treatment and prevention of HIV Geneva World Health Organization.
132. Lewden C, Gabillard D, Minga A, Ekouevi DK, Avit D, et al. (2012) CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa. J Acquir Immune Defic Syndr 59: 213-219.